Dimethyl fumarate (Tecfidera®) is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (MS).
|04/02/2014||06/03/2014||Full Pharmacoeconomic Evaluation Recommended|
|16/07/2014||14/01/2015||Reimbursement not recommended|
Following NCPE assessment of the company submission, dimethyl fumarate (Tecfidera®) is not considered cost-effective for the treatment of adult patients with relapsing remitting MS and therefore is not recommended for reimbursement at the submitted price.
Following pricing negotiation, the HSE has approved reimbursement of Tecfidera® under the High Tech Drugs Scheme.